OPK - OPKO Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305-575-4100
http://www.opko.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees6,030

Key Executives

NameTitlePayExercisedYear Born
Dr. Philip FrostChairman and Chief Exec. Officer970.6kN/A1936
Dr. Jane H. Hsiao Ph.D., MBAVice Chairman and Chief Technical Officer970.6kN/A1947
Mr. Adam E. LogalChief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer610.6kN/A1978
Mr. Steven D. RubinExec. VP of Admin. and Director820.6k2.29M1960
Ms. Kate Inman Esq.Deputy Gen. Counsel and Sec.N/AN/A1973
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Corporate Governance

OPKO Health, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.